Effect of transcatheter arterial chemoembolization combined with radiofrequency ablation and cytokine-induced killer cells infusion on small hepatocellular carcinoma

( views:, downloads: )
Author:
LI Wang(State Key Laboratory of Oncology in South China, Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China)
HUANG Zi-lin(State Key Laboratory of Oncology in South China, Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China)
ZHANG Liang(State Key Laboratory of Oncology in South China, Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China)
ZHAO Ming(State Key Laboratory of Oncology in South China, Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China)
WU Pei-hong(State Key Laboratory of Oncology in South China, Department of Imaging and Interventional Radiology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China)
Journal Title:
CHINESE JOURNAL OF BIOMEDICAL ENGINEERING
Issue:
Volume 15, Issue 01, 2009
DOI:
10.3760/cma.j.issn.1674-1927.2009.01.002
Key Word:
Liver neoplasms;Embolization, therapeutic;Ablation, radiofrequency;Transcatheter arterial chemoembolization;Immunotherapy, adoptive

Abstract: Objective To evaluate the efficacy of autologous eytokine-induced killer cells (CIKs) infusion after transcatheter arterial chemoembelization (TACE) combined with radiofrequency ablation (RFA) for patients with small hepatocellular carcinoma (SHCC) and the immunologic index changes of patients with SHCC after CIKs adoptive immunotherapy. Methods Forty-three patients with SHCC in our hospital from February 2004 to February 2006 were recruited and were divided into two groups after receiving TACE and CT-guided RFA. The study group (21 cases) received autologous CIKs infusion more than 4 times, and the number of CIKs infused ranged from 1.1×1010 to 1.5×1010 every time. The control group (22 cases) only received TACE combined with RFA. The levels of T lymphocyte subsets and native killer (NK) cells in peripheral blood of patients with SHCC in study group before and after CIKs infusion were detected. All the patients in both groups were evaluated every 1 to 2 months during follow-up. Results (1) 1-, 2-and 3-year intrabepatic accumulative recurrence rates in study group were 9.5%, 14.3% and 19.0% respectively, and those in control group were 9.1%, 22.3%and 27.3% respectively. 1-, 2- and 3-year survival rates in study group were 95.2%, 85. 7% and 76.2% respectively, and those in control group were 95.5%, 81.8% and 68.2% respectively (P=0.558). (2)The percentages of CD3+, CD4+ and CD56+ effect cells and the proportion of CD4+/CD8+ were obviously increased after CIKs infusion (P<0.05) ; while the percentages of CD8+ and CD3+CD56+ effect cells were decreased in study group(P<0.05). Conclusion Sequential CIKs infusion after TACE combined with RFA can improve immune function of patients with SHCC, and may play an important role in reducing recurrence rate of SHCC and prolonging the survival time.

  • [1]Chen MS,Zhang YQ,Li JQ,et al.Results of surgical resectionon 250 patients with small hepatocelular carcinoma.Chin J Cancer,1998,17:362-364.
  • [2]Arii S,Yamaoka Y,Futagawa S,et al.Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas:a retrospective and nationwide survey in Japan.Hepatology,2000,32:1224-1229.
  • [3]吴孟超,陈汉,沈锋.原发性肝癌的外科治疗--附5524例报告.中华外科杂志,2001,39:25-28.
  • [4]Zhou XD,Tang ZY,Yang BH,et al.Experience of 1000 patients who underwent hepatoctomy for small hepatocellular carcinoma.Cancer,2001,91:1479-1486.
  • [5]Bruix J,Sherman M.Management of hepatocellular carcinoma.Hepatology,2005,42:1208-1236.
  • [6]陈晓琳.戴勇,李富荣,等.恶性肿瘤患者T淋巴细胞及NK细胞功能研究及临床意义.中国现代医学杂志,2002,12:34-38.
  • [7]黄丽惜,周启明,夏建川.微创联合自体CIK细胞治疗原发性肝癌的安全性及有效性评价.广东医学,2007,28:1466-1468.
  • [8]吴沛宏.原发性肝癌的介入治疗基本模式的转变-TACE治疗到TACE联合消融治疗.中华放射学杂志,2003,37:870-871.
  • [9]陈积圣,巴明臣.原发性肝细胞癌的介入治疗现状及存在问题.新医学,2005,36:423-424.
  • [10]王建华.肝癌综合介入治疗的现状.中华肝脏病杂志,2005,13:721-723.
  • [11]赵明,吴沛宏,谢强,等.活体猪肝第一,二肝门区的单极灌注式射频消融的安全性观察.癌症,2007,26:1194-1198.
  • [12]Choi D,Lim HK,Kim MJ,et al.Recurrent hepatocellular carcinoma:percutaneous radiofrequency ablation afterhepatectomy.Radiology,2004,230:135-141.
  • [13]吴汉平,冯敢生.肝癌介入治疗的现状与展望.临床放射学杂志,2005,24:273-276.
  • [14]吴沛宏,张福君,赵明.等.肝动脉栓塞化疗联合CT导向射频消融术治疗中、晚期肝癌的评价.中华放射学杂志,2003,37:901-904.
  • [15]陈晓明,罗鹏飞,邵培坚,等.肝癌栓塞化疗生存3年以上48例临床分析.中华放射学杂志,1995,29:876-877.
  • [16]Takayama T,Sekine T,Makuuehi M,et al.Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:a randomised trial.Lancet,2000,356:802-807.
  • [17]孔丽,姚树坤,刘金星,等.原发性肝癌患者细胞免疫功能变化及其与转归的关系.中华肝脏病杂志,2005,13:194-197.
  • [18]施明,张冰,汤紫荣,等.肝癌患者自体细胞因子诱导杀伤细胞治疗后免疫活性细胞的检测及其临床意义.中华医学杂志,2003,83:20492-053.
  • [19]Scheffold C,Brandt K,Johnston V,et al.Potential of autologons immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.Bone Marrow Transplant,1995,15:33-39.
  • [20]赵明,曾益新,吴沛宏,等.经肝动脉栓塞化疗序贯联合射频消融和细胞因子诱导的杀伤细胞治疗肝细胞癌的随机研究.中华医学杂志,2006,86:1823-1828.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn